American College Of Surgeons

American College of Surgeons, a non-profit professional organization headquartered in Chicago, Illinois, operates as a prime contractor delivering cancer program accreditation, surgical quality improvement memberships, and specialized medical training services to federal healthcare agencies, with a portfolio dominated by the Department of Veterans Affairs and the Defense Health Agency. All 792 recent awards are prime contracts or grants; the organization does not pursue subcontract work.

ACS's federal footprint centers on three core service lines grounded in concrete capability delivery. Commission on Cancer (CoC) accreditation — site surveys, program evaluations, and quality standard maintenance for VA and military cancer programs — dominates by award count and spans nearly every VA Veterans Integrated Service Network, with individual annual accreditation fees typically ranging from $10,926 to $27,364. National Surgical Quality Improvement Program (NSQIP) memberships and training services for adult, pediatric, bariatric, and trauma specialties across Department of Defense military treatment facilities anchor the largest single contract vehicle: a $13.76 billion indefinite delivery contract awarded by the Defense Health Agency in June 2025 running through June 1, 2030, which generated $1.37 million in a June 2025 delivery order and $1.29 million in a May 2024 delivery order for risk-adjusted surgical outcome measures, training, and online support. Advanced Trauma Life Support (ATLS) training and education materials — student manuals, instructor courses, and training fees — represent a third major line, evidenced by a $239 thousand order from the Defense Health Agency in January 2026 and a $156 thousand purchase order for FY24 ATLS student manuals with application through September 2028. ACS also licenses the American Joint Committee on Cancer (AJCC) cancer staging system and API access to federal agencies; the National Cancer Institute awarded $718,331 in July 2024 for continued access to the 8th Edition Cancer Staging Manual and Version 9 system supporting the SEER Program through June 2029.

Customer concentration is heavily skewed toward DoD and VA networks. The Defense Health Agency anchors 40 awards carrying $46.2 million combined potential value — roughly 76% of ACS's entire award portfolio value — making it overwhelmingly the dominant customer. The Department of the Army Medical Command (72 awards, $992 thousand), VA Veterans Integrated Service Network 10 (47 awards, $434 thousand), VA Veterans Integrated Service Network 17 (33 awards, $652 thousand), and VA Veterans Integrated Service Network 1 (25 awards, $611 thousand) round out the top five by count but contribute modestly to total dollars; their awards are clustered in the $10,926 to $13,659 range. This divergence between count and value reflects a business model in which ACS sells high-volume, low-unit-price accreditation subscriptions to individual VA networks while anchoring revenue on larger, multi-year surgical quality platforms at DoD.

ACS holds at least four named indefinite delivery vehicles. The Defense Health Agency IDC (HT001120D0004) valued at $13.76 million through June 2030 is the flagship vehicle, with 8 task orders placed to date spanning NSQIP membership and training. A single-award IDC with VA Veterans Integrated Service Network 8 valued at $138,068 through December 2028 covers annual CoC accreditation fees (3 delivery orders issued to date). A five-year single-award IDC with VA Veterans Integrated Service Network 23, awarded November 2025, carries a ceiling of $150,938 for CoC accreditation at two VA medical centers through October 2030. A separate BPA with VA Veterans Integrated Service Network 1, established September 2026, holds a $350,000 ceiling through January 2027 for Commission on Cancer services.

Federal grant activity rounds out the footprint. ACS holds a cooperative agreement with the Uniformed Services University of the Health Sciences for the Military Health System Strategic Partnership (MHSSPACS), awarded September 2024 and running through September 2027. A second cooperative agreement with the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion, awarded September 2023 through September 2028, funds the American Joint Committee on Cancer's work on uniform cancer data surveillance standards and interoperability supporting the National Program of Cancer Registries. ACS also acts as a sub-recipient on grant work: University of Texas at Austin funded ACS sub-awards in October 2024 and October 2025 for the National Emergency Medical Services for Children (EMSC) Resource Centers Demonstration, and the Regents of the University of Michigan funded a May 2024 sub-award to study Commission on Cancer accredited programs' implementation of operative standards.

Awards per year have declined modestly—from 43 in 2022 to 14 through mid-2026—reflecting a shift in procurement patterns toward larger, multi-year vehicles and away from granular annual purchase orders. Seventeen awards (combined potential value $3 million) face ultimate completion within the next twenty-four months, representing moderate recompete exposure concentrated in VA accreditation renewals.

ACS competes exclusively full-and-open; no set-asides designate any of the awards in the source. The organization's federal posture is defined by the sole-source authority applied to many VA CoC accreditation awards (FAR 13.106-1(b)(2)), reflecting determination that ACS possesses unique qualifications and specialized expertise in cancer program accreditation that cannot be replicated by other vendors.